Semi-quantitative analysis showed immunoreactivity of less than 10% of tumor cells in 16 (59.3%) cases, 10% to 25% in 9 (33.3%) cases, and 26% to 50% in 2 (7.4%) cases of p53 positive RCC tumors. Here, TP53 is linked to neoplasm.